Skip to main content

Advertisement

Table 1 Patient and tumor characteristics by Prosigna (PAM50) subtype

From: The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

  Total study set Molecular subtype
Luminal A Luminal B Basal-like Her2-E
Characteristics N % N % N % N % N %
Number of patients 460 161 35 118 27 61 13 120 26
Age
  < 40 years 96 21 23 14 26 22 19 31 28 23
 40–49 years 233 51 94 58 63 53 25 41 51 43
 50–59 years 131 28 44 27 29 25 17 28 41 34
Lymph nodes excised
 None 19 4 8 5 7 6 1 2 3 3
 1–3 110 24 42 26 27 23 14 23 27 23
 4–9 268 58 97 60 67 57 39 64 65 54
  > 9 6 14 14 9 17 14 7 11 25 21
Lymph node status
 Negative 43 9 16 10 4 3 10 16 13 11
 1–3 positive 271 59 106 66 72 61 33 54 60 50
 4+ positive 127 28 31 19 35 30 17 28 44 37
 Unknown 19 4 8 5 7 6 1 2 3 3
Tumor size
 0–20 mm 132 29 60 37 36 31 14 23 22 18
 21–50 mm 239 52 77 48 61 52 30 49 71 59
  > 50 mm 85 18 24 15 21 18 13 21 27 23
 Unknown 4 1 0 0 0 0 4 7 0 0
Deep fascia invasion
 Absent 346 75 127 79 93 79 45 74 81 68
 Present 109 24 32 20 25 21 15 25 37 31
 Unknown 5 1 2 1 0 0 1 2 2 2
Histologic type
 Ductal carcinoma 393 85 132 82 99 84 52 85 110 92
 Lobular carcinoma 33 7 16 10 13 11 1 2 3 3
 Other 28 6 11 7 5 4 6 10 6 5
 Unknown 6 1 2 1 1 1 2 3 1 1
Malignancy gradea
 Grade I 65 17 46 35 15 15 1 2 3 3
 Grade II 242 62 81 61 73 74 22 42 66 60
 Grade III 86 22 5 4 11 11 29 56 41 37
HR status
 Positive 329 72 146 91 112 95 6 10 65 54
 Negative 114 25 6 4 5 4 52 85 51 43
 Unknown 17 4 9 6 1 1 3 5 4 3
Systemic treatment
 Control or levamisole 113 25 37 23 34 29 10 16 32 27
 C or CMF 347 75 124 77 84 71 51 84 88 73
ROR score groups
 Low (0–51) 155 34 135 84 2 2 14 23 4 3
 Intermediate (52–71) 148 32 26 16 50 42 40 66 32 27
 High (72–100) 157 34 0 0 66 56 7 11 84 70
  1. PAM50 prediction analysis of microarray 50, C cyclophosphamide, CMF cyclophosphamide, methotrexate and fluorouracil, HR hormone receptor, Her2-E human epidermal growth factor receptor 2-enriched, ROR risk of recurrence
  2. aDuctal carcinomas only